九州通医药集团股份有限公司 章 程 （2023 年 8 月修订） 2023 年 8 月 目 录 第一章 总则 第五章 董事会 第一节 董事 第二节 董事会 第六章 总经理及其他高级管理人员 第七章 监事会 第一节 监事 第二节 监事会 第八章 财务会计制度、利润分配和审计 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东大会 第一节 股东 第二节 股东大会的一般规定 第三节 股东大会的召集 第四节 股东大会的提案与通知 第五节 股东大会的召开 第六节 股东大会的表决和决议 第一节 合并、分立、增资和减资 第二节 解散和清算 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第九章 通知和公告 第一节 通知 第二节 公告 第十章 合并、分立、增资、减资、解散和清算 第十一章 修改章程 第十二章 附则 第四条 公司注册名称： 中文名称：九州通医药集团股份有限公司 英文名称：JOINTOWN PHARMACEUTICAL GROUP CO., LTD. 九州通医药集团股份有限公司章程 第一章 总则 第一条 为维护公司、股东和债权人 ...

根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董 事规则》以及《公司章程》等相关规定，我们作为九州通医药集团股份有限公司 （以下简称"公司"）的独立董事，本着认真负责的工作态度，基于独立判断的 立场，对公司第五届董事会第二十五次会议审议的相关事项发表如下独立意见： 九州通医药集团股份有限公司独立董事 关于第五届董事会第二十五次会议相关事项的独立意见 2 一、关于公司 2023 年半年度资本公积金转增股本预案的独立意见 公司本次资本公积金转增股本方案符合公司长远发展需要，符合《上海证券 交易所上市公司自律监管指引第 1 号—规范运作》《上海证券交易所股票上市规 则》以及《公司章程》等相关规定，不存在损害公司股东特别是中小投资者利益 的情形。因此，我们一致同意关于公司 2023 年半年度资本公积金转增股本预案 的议案，并同意将该议案提交公司股东大会审议。 二、关于公司 2023 年半年度审计费用的独立意见 公司根据《上海证券交易所股票上市规则》等相关规定，对 2023 年半年度 财务报告进行审计，并按照市场公允定价的原则，拟定相关审计费用，符合法律、 法规和《公司章程》的相关规定，不存在损害公 ...

证券代码：600998 证券简称：九州通 公告编号：临2023-087 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 2023 年 8 月 27 日，九州通医药集团股份有限公司（以下简称"公司"）召 开第五届董事会第二十五次会议，审议通过了《关于公司 2023 年半年度审计费 用的议案》，根据市场公允定价的原则，同意公司 2023 年半年度审计费用为 135 万元人民币。具体情况如下： 一、公司 2023 年半年度审计费用情况 公司于 2023 年 5 月 19 日召开 2022 年年度股东大会，审议通过了《关于公 司聘任中审众环会计师事务所（特殊普通合伙）为 2023 年审计机构的议案》， 同意续聘中审众环会计师事务所（特殊普通合伙）为公司 2023 年审计机构。现 因公司拟实施 2023 年半年度资本公积金转增股本的预案，依据《上海证券交易 所股票上市规则》等相关规定，需对 2023 年半年度财务报告进行审计；经双方 友好协商并根据市场公允定价的原则，公司 2023 年半年度审计费用拟为 135 万 元人民币。 二、公司 2023 ...

证券代码：600998 证券简称：九州通 公告编号：临 2023-081 九州通医药集团股份有限公司 关于召开 2023 年半年度业绩说明会的预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间：2023 年 9 月 1 日（星期五）上午 11:00-12:00 ●问题征集：投资者可于 2023 年 8 月 25 日（星期五）至 8 月 31 日（星期 四）登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 jztdmc@jztey.com 进行提问；公司将在业绩说明会上对投资者普遍关注的问题进 行回答。 九州通医药集团股份有限公司（以下简称"公司"）将于 2023 年 8 月 29 日 发布 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年 度经营成果、业绩亮点、权益分派，以及公司向"新零售、新产品、互联网医疗、 不动产证券化（REITs）"四大新战略转型的情况，公司计划于 2023 年 9 月 1 日 上午 11:00-12:00 在上海证券交易所 ...

证券代码：600998 证券简称：九州通 公告编号：临 2023-079 九州通医药集团股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 被担保人名称及是否为上市公司关联人：被担保人包括陕西九州通医药有限 公司、河南九州通医药有限公司等 40 家控股子公司（含天津九州通达医药有限 公司、厦门九州通医药有限公司等 17 家全资子公司），不存在关联担保； ● 本次担保金额及已实际提供的担保余额：九州通医药集团股份有限公司（以下 简称"公司"或"九州通集团"）7 月新增担保金额合计 320,705.00 万元，同时解除 担保金额合计 166,214.00 万元。截至 2023 年 7 月 31 日，公司提供担保余额为 2,357,915.00 万元，主要为对控股子公司（含全资子公司）及其下属企业的担保， 不含控股子公司对九州通集团的担保，公司拥有被担保方的控制权，且其现有经 营状况良好，因此担保风险可控； ● 本次担保是否有反担保：有； ● 对外担保逾期的累计数量： ...

证券代码：600998 证券简称：九州通 公告编号：临 2023-049 九州通医药集团股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开主题：九州通 2022 年度暨 2023 年第一季度业绩说明会 ●会议召开时间：2023 年 5 月 15 日（星期一）下午 13:00-14:30 ●会议召开方式：视频录播结合网络互动 1 二、网络参会方式 （一）为方便广大投资者参与本次业绩说明会，所有投资者可点击以下链接 观看本次业绩说明会并参与互动交流。 1、上海证券交易所上证路演中心（http://roadshow.sseinfo.com/） ●投资者参会平台： 1、上海证券交易所上证路演中心（http://roadshow.sseinfo.com/） 2、中国证券报·中证网路演中心（https://www.cs.com.cn/roadshow/yjsmh/） 3、同花顺路演平台（http://board.10jqka.c ...

证券代码：600998 证券简称：九州通 公告编号：临 2023-047 九州通医药集团股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间：2023 年 5 月 15 日（星期一）下午 13:00-14:30 ●会议召开地点：上海证券交易所上证路演中心（http://roadshow.sseinfo.com /） ●会议召开方式：上证路演中心视频录播和网络互动 ●问题征集：投资者可于 2023 年 5 月 8 日（星期一）至 5 月 12 日（星期五） 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 jztdmc@jztey.com 进行提问；公司将在业绩说明会上对投资者普遍关注的问题进 行回答。 九州通医药集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日 发布公司 2022 年年度报告和 2023 年第一季度报告。2022 年，公司在外部环境 复杂多变、行业改革不断深化的背景 ...

Financial Performance - The company's revenue reached 140.424 billion CNY in 2022, a year-on-year increase of 14.72%[4] - The net profit attributable to shareholders, excluding non-recurring items, was 1.734 billion CNY, with a year-on-year growth rate of 23.56%[4] - The cash flow from operating activities improved significantly, totaling 3.986 billion CNY, an increase of 15.24% compared to the previous year[4] - The company's operating revenue for 2022 was ¥140.42 billion, representing a 14.72% increase compared to ¥122.41 billion in 2021[36] - The net profit attributable to shareholders decreased by 14.84% to ¥2.08 billion from ¥2.45 billion in the previous year[36] - The net profit after deducting non-recurring gains and losses increased by 23.56% to ¥1.73 billion, driven by steady growth in pharmaceutical distribution and emerging businesses[38] - The total cash dividend for 2022 amounted to 1,338,303,571.50 RMB, accounting for 64.19% of the net profit attributable to shareholders[16] Business Growth and Expansion - The company plans to add 6,700 new direct and franchise stores in 2023, aiming for a total of over 30,000 stores by 2025[10] - The new product sales are expected to grow by no less than 20% in 2023, with a target of exceeding 15% of total sales by 2025[10] - The company plans to continue expanding its emerging businesses, including pharmaceutical retail and logistics services, to drive future growth[38] - The "Wandian Franchise" initiative has expanded to over 13,000 stores across 31 provinces, with plans to exceed 30,000 stores by 2025[59] - The company has established partnerships with 14 public medical institutions for internet hospitals, achieving a prescription transfer scale of approximately 60 million CNY during the reporting period[64] Digital Transformation and Technology - The company has deepened its digital transformation, with projects like "Smart Medicine" and AI-driven procurement being implemented[9] - The company is actively promoting the "Wanshop Franchise" plan to accelerate the transformation of its business model[51] - The company has developed a comprehensive digital management system for franchise stores, enhancing operational efficiency and service capabilities[60] - The company has launched a digital transformation project focusing on 16 sub-projects to enhance customer experience and empower external business operations[152] - The company has developed 54 patents related to logistics intelligent equipment, including innovations in automated picking technology[144] E-commerce and Online Services - The B2B e-commerce platform generated 11.642 billion CNY in revenue, up 11.20% year-on-year[5] - The retail e-commerce service platform achieved 5.459 billion CNY in revenue, reflecting a growth of 36.46%[5] - The company's B2C e-commerce sales revenue reached nearly 1 billion CNY, with over 27 million C-end users accumulated, representing a 59% year-on-year growth[61] - The "Mi Health" service platform has over 400,000 paid users and processed over 630,000 prescription transfer orders, with a total insurance fulfillment amount of 250 million CNY, marking a 2,759% increase in service revenue from the previous year[62] - The company achieved an annual revenue of 11.642 billion CNY from the Yaojiu B2B e-commerce platform, accounting for 8.30% of total revenue, with over 400,000 registered users and 350,000 active users[53] Supply Chain and Logistics - The company has established a "trillion-level" pharmaceutical supply chain service platform, integrating "pharmaceutical distribution + logistics + product promotion" as a comprehensive service model[13] - The company operates over 141 pharmaceutical logistics centers and distribution points across 31 provincial capitals and 110 prefecture-level cities, with a total building area exceeding 4.2 million square meters[68] - The logistics integration of Bb/BC has been implemented in 12 companies, aiming for full coverage of this capability in the next three years, with a daily collection rate exceeding 99%[65] - The logistics supply chain solutions business has achieved a peak daily order volume of 250,000 since the launch of the first BC integrated warehouse in Hangzhou, with a monthly peak of 5 million orders and an outbound accuracy rate of 99.999%[71] - The company has developed a unique pharmaceutical cold chain logistics product called "Jiulian Tong," which includes three main components: storage, transportation, and last-mile delivery[142] Corporate Governance and Social Responsibility - The board proposed a cash dividend of 5 RMB per 10 shares (including tax) and a capital reserve conversion of 4.9 shares for every 10 shares, increasing the total share capital to 2,768,251,909 shares[15] - The company donated nearly 30 million CNY in various forms, including emergency medical supplies and educational support, demonstrating its commitment to social responsibility[76] - The company donated over 2.62 million CNY worth of emergency medicines to support local pandemic control efforts in several targeted counties[78] Market Trends and Regulatory Environment - The pharmaceutical circulation market in China reached a total sales volume of 260.64 billion yuan, with a year-on-year growth of 8.5%, indicating an acceleration in market growth[99] - The government has relaxed restrictions on online first consultations for common and chronic diseases, which is expected to accelerate the growth of the Internet healthcare sector[89] - The national strategy includes incorporating eligible Internet medical services into medical insurance payment coverage, which will further support the growth of Internet healthcare services[88] - The introduction of supportive policies for public REITs since 2020 has created significant growth opportunities in the public REITs market, enhancing the investment landscape[94] Research and Development - Research and development expenses decreased by 8.49% to ¥178.39 million from ¥194.94 million in the previous year[198] - The company is focusing on expanding its digital health management capabilities and enhancing its product development through a new ecosystem model[197] - The company aims to reduce birth defect rates by 1% through the application of genomic testing technologies in clinical settings[197]

Financial Performance - The company's operating revenue for Q1 2023 was CNY 42,092,541,357, representing a year-on-year increase of 19.75%[4] - Net profit attributable to shareholders was CNY 561,172,724.88, up 24.06% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 573,181,108.58, reflecting a growth of 20.10% year-on-year[4] - The basic earnings per share for the period was CNY 0.29, an increase of 26.09% from the previous year[5] - Total operating revenue for Q1 2023 reached RMB 42.09 billion, a 19.7% increase from RMB 35.15 billion in Q1 2022[23] - Net profit for Q1 2023 was RMB 598.44 million, up 25.1% from RMB 478.21 million in Q1 2022[24] - Operating profit for Q1 2023 was RMB 729.92 million, representing a 26.2% increase compared to RMB 578.34 million in Q1 2022[24] - The company reported a total comprehensive income of RMB 592.90 million for Q1 2023, compared to RMB 501.73 million in Q1 2022[25] - Basic earnings per share for Q1 2023 were RMB 0.29, an increase from RMB 0.23 in Q1 2022[25] Asset and Liability Management - The total assets at the end of the reporting period amounted to CNY 96,415,023,973.10, a 4.49% increase from the end of the previous year[5] - The total current assets increased to approximately 79.57 billion yuan, up from 75.66 billion yuan in the previous period, reflecting a growth of about 5.3%[20] - The company's total assets reached approximately 96.42 billion yuan, compared to 92.27 billion yuan in the previous period, marking an increase of about 4.6%[22] - Short-term borrowings rose to approximately 12.58 billion yuan, up from 11.49 billion yuan, indicating an increase of about 9.5%[21] - The total liabilities increased to approximately 67.21 billion yuan, compared to 63.59 billion yuan, reflecting a growth of about 5.1%[21] - The company's equity attributable to shareholders reached approximately 25.20 billion yuan, up from 24.64 billion yuan, indicating an increase of about 2.3%[21] Cash Flow Analysis - The company's cash flow from operating activities showed a net outflow of CNY 3,021,589,444.65, a decrease of 14.19% year-on-year[4] - Cash flow from operating activities in Q1 2023 was RMB 34.09 billion, an increase from RMB 29.35 billion in Q1 2022[26] - The net cash flow from operating activities was -3,021,589,444.65 RMB, compared to -2,646,124,039.84 RMB in the previous year, indicating a decline of approximately 14.2%[27] - Total cash outflow from operating activities amounted to 37,112,112,985.91 RMB, an increase of 15.5% from 31,995,646,766.24 RMB year-over-year[27] - The net cash flow from investing activities was -177,134,497.43 RMB, a significant decrease from 1,652,589,306.34 RMB in the previous year[27] - Cash inflow from financing activities totaled 8,405,285,106.46 RMB, down 14.1% from 9,782,021,294.34 RMB year-over-year[27] - The net cash flow from financing activities was 1,461,533,978.13 RMB, compared to -249,314,751.27 RMB in the previous year, showing a positive turnaround[27] - The ending balance of cash and cash equivalents was 5,922,400,416.67 RMB, slightly up from 5,839,027,202.15 RMB year-over-year[28] Business Growth and Strategy - The revenue from the brand promotion business grew by 33.99%, with gross profit increasing by 92.78% compared to the previous year[6] - The revenue from the pharmaceutical retail business surged by 62.24%, with gross profit rising by 68.33% year-on-year[6] - The revenue from third-party logistics increased by 36.99%, with gross profit up by 55.75% compared to the same period last year[6] - The company has exceeded 13,000 self-operated and franchised pharmacies under the "Ten Thousand Store Franchise" plan, covering 1,122 cities across 31 provinces, with a target of over 30,000 stores by 2025[18] - The "Mi Health" service platform has surpassed 400,000 paying users, with over 630,000 prescription transfer orders and an insurance fulfillment amount of 250 million yuan[18] - The company has launched six integrated "BC warehouses" in Guangdong, Shanghai, Jiangsu, Hubei, Zhejiang, and Tianjin, aiming for full coverage of "Bb/BC warehouse integration" capabilities in the next three years[18] - The company has completed the "Bb integration" transformation for 12 logistics companies, achieving "zero inventory" for clients and sharing 100,000 product specifications[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,486, with the top ten shareholders holding a combined 56.85% of shares[11] - Shanghai Hongkang Industrial Investment Co., Ltd. holds 404,441,118 shares, accounting for 21.58% of total shares, with 240,240,000 shares pledged[11] - Lion Dragon International Group (Hong Kong) Limited holds 213,894,000 shares, representing 11.41% of total shares[11] - The top ten preferred shareholders hold a total of 20 million shares, with China Orient Asset Management Co., Ltd. holding 5 million shares, accounting for 25%[14] - The top ten shareholders include several entities with pledged shares, indicating a potential risk in shareholder stability[11] Future Initiatives - The company plans to initiate a public REITs issuance for pharmaceutical logistics and warehousing assets, aiming to raise up to 3 billion RMB[17] - The REITs project is expected to enhance the company's financial metrics and improve asset liquidity, reducing reliance on traditional debt financing[17] - The company is actively responding to national policy initiatives by launching the REITs project, which is expected to positively impact its market presence[17] - The company aims to activate over 3 million square meters of pharmaceutical logistics and warehousing assets through the REITs initiative[17]